title: Clinical study on carboplatin for treating pediatric patients with Wilms tumors.
abstract: This analysis was conducted to evaluate the efficacy and safety of carboplatin based chemotherapy in treating pediatric patients with Wilms tumors.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of carboplatin based regimens on response and safety for pediatric patients with Wilms tumors were identified using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated.
  
  
  RESULTS
  In carboplatin based regimens, 4 clinical studies which including 127 patients with advanced Wilms tumors were considered eligible for inclusion. With this carboplatin based chemotherapy, 2 clinical studies included carboplatin, ifosfamide and etoposide. Systemic analysis suggested that, in all patients, the pooled PR was 64.5% (82/127) in carboplatin based regimens. Thrombocytopenia and leukocytopenia were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related death occurred with carboplatin based treatment.
  
  
  CONCLUSIONS
  This systemic analysis suggests that carboplatin based regimens are associated with a reasonable response rate and accepted toxicities for treating pediatric patients with Wilms tumors.
authors.affiliation: Shiyan Taihe Hospital of Hubei Province Department of Pediatrics, The Affiliated Hospital of Hubei Medical College, Shiyan, China E-mail : zyong885900@sohu.com.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ling-Li
authors.initials: LL
authors.lastname: Sun
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Guo-Jia
authors.initials: GJ
authors.lastname: Mao
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002648:Child; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide